The Global Size, Developments Status, Trends are Breast Cancer Therapy Market was valued at USD 19.02 billion in 2018 and is expected to reach USD 40.47 billion by the year 2026, at a CAGR of 10.6%. Breast cancer is a tumor that is found in the mammary tissue. A lump is mostly seen in the breast; It shows symptoms like change in the shape, a newly-inverted nipple, or a red or scaly patch of skin and fluid coming from the nipple. WHO had signified that breast cancer affects about 2.1 million women every year and is the primary cause of deaths associated with malignancy. In the year 2018, it was observed that 627,000 women died from breast cancer, i.e., it accounts for 15% of total deaths.Ask for Sample Report @ www.reportsanddata.com/sample-enquiry-form/2666
Rise in the healthcare awareness among individual’s disease and treatment, early detection of the cancer, better surgical and medical treatment, R&D initiatives, and technological advancement are the factors driving the growth of the breast cancer therapy market. However, High expenditure in the treatment is restraining the growth of the market. Breast carcinoma had affected many women in North America. It was estimated that about 500 women are diagnosed in the U.S. each day with breast carcinoma. A sedentary lifestyle and genetic mutation are the factors associated with the risk of breast carcinoma in the region, leading to rising in demand for breast carcinoma treatments.
Hoffmann-La Roche Ltd; Pfizer Inc.; AstraZeneca; Novartis AG; Astellas Pharma Inc.; and Eli Lilly Inc, Eisai Co., Ltd., AbbVie, Inc., Janssen Global Services LLC and Merck are the key players in the Breast cancer therapy market.
Request a customization of the report @ www.reportsanddata.com/request-customization-form/2666
For the purpose of this report, Reports and Data have segmented the Breast cancer therapy market on the basis of drugs, radiation therapies, end use and regions.
Drugs Outlook (Revenue in Million USD; 2016–2026)
• Chemotherapy
o Anthracyclines
o Taxanes
o Tamoxifen
o Antimetabolites
o Others
• Hormone Therapy
o Tamoxifen
o Fulvestrant
o Aromatase inhibitors
• Targeted therapy
o Trastuzumab
o Neratinib
o T-DM1
o Others
• Immunotherapy
o Atezolizumab
o Pembrolizumab
Radiation therapies Outlook (Revenue in Million USD; 2017–2024)
• External radiation.
• Intra-operative radiation
• Brachytherapy
End Use Outlook (Revenue in Million USD; 2017–2024)
• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Retail Pharmacies
Regional Outlook (Revenue in Million USD; 2016–2026)
• North America
• Europe
• Asia Pacific
• Middle East & Africa
• Latin America
o Brazil
To know more about the report @ www.reportsanddata.com/report-detail/breast-cancer-therapy-market
Thank you for reading our report. Customization of the report is available based on the client’s requirements. For more details, kindly connect with us, and our team will ensure the report is suited to meet your requirements.